

Remarks/Arguments:

The Examiner has required restriction to one of eight groups of inventions. In response, applicants hereby elect Group I, claims 1-10, 17-20, drawn to a compound or composition of formula (1) where Z = CH, r = 1, and A = phenylene.

The Examiner has further required election of a single disclosed species. In response, applicants hereby elect the compound of Example 5, namely 2-chloro-*N*-[(1*R*,2*R*)-1-(hydroxymethyl)-2,3-dihydro-1*H*-inden-2-yl]-6*H*-thieno[2,3-*b*]pyrrole-5-carboxamide. As amended, claims 1, 3, 5, 6, 10, and 16-23 read on the elected species.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application

Applicants believe the application is in condition for allowance, which action is respectfully requested.

A petition for a three-month extension of time is being filed herewith. The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101159-1P US.

Respectfully submitted,
/John X Haberman/

Name: John X Haberman
Dated: September 16, 2008
Reg. No.: 55,236
Phone No.: 781-839-4736

Global Intellectual Property, Patents
AstraZeneca R&D Boston,
35 Gatehouse Drive
Waltham, MA 02451